TOTUM•448 is an innovative plant-based patented active substance developed by Valbiotis, a young French SME, to counteract the development of metabolic liver diseases (NAFL and NASH1 In two
Internationally, the signing of licensing or distribution partnerships with major players in nutrition and healthcare. In France, Valbiotis has chosen to internalize its commercial operations
TOTUM•070 demonstrates excellent results in volunteers with blood LDL cholesterol levels above 130 mg/dl at randomization, its commercially targeted population and the primary subpopulation of the
TOTUM•070 demonstrates excellent results in volunteers with blood LDL cholesterol levels above 130 mg/dl at randomization, its commercially targeted population and the primary subpopulation of the HEART study:Increased and lasting efficacy on blood LDL cholesterol levels, with a reduction of 13.7% after three months.
A cash position of €15.4 million at June 30, 2022. Financial visibility until the last quarter of 2023, excluding potential additional revenues. Continued execution of the strategic